Por: The Boston Globe Business July 07, 2023
US regulators on Thursday gave full approval, for the first time, to a drug shown to modestly slow cognitive decline in people with early Alzheimer’s. The medicine, called Leqembi, carries risks of serious side effects, but has also given hope to millions affected by the memory-ravaging disease.The treatment will cost $26,500 a year per patient, according to Biogen, the Cambridge drug maker, and its Japanese business partner Eisai, which... + full article
Fox Business USA Business December 30, 2022
Check out what's clicking on FoxBusiness.com A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the process rife with irregularities.The drug in question is Aduhelm, which was... + más
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
BioVie president and CEO Cuong Do discusses the positive results of its Parkinson's and Alzheimer's phase 2 trials and explains how its NE3107 drug could reverse the biological clock on 'Varney & Co.' An 18-month-long investigation conducted by the House... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Probe: Alzheimer's drug approval 'rife with irregularities' | 10 WBNS
ABC News USA Health December 30, 2022
WASHINGTON -- The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees detailed... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial | CNBC
Associated Press USA Politics December 30, 2022
WASHINGTON (AP) — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees... + más
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
WPLG Local 10 USA Politics December 30, 2022
WASHINGTON – The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees detailed... + más
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
About iurex | Privacy Policy | Disclaimer |